Revelle Aesthetics, Inc. (Revelle) — a VC-backed Silicon Valley MedTech company — achieved an extended FDA clearance for its precision cellulite release device, Avéli™. Marking another key milestone for the Company, Avéli is now indicated for long-term reduction in the appearance of cellulite in the buttocks and thigh areas of adult females as supported by clinical data demonstrating treatment benefits through one year of observation.
‘For far too long, millions of women have struggled to feel comfortable in their own skin because of their cellulite and have been settling for less than effective treatment options. Avéli is setting out to change this by finally providing women with a meaningful and lasting solution that targets their cellulite in the areas that have frustrated them the most, their buttocks and thighs,’ said Caroline Van Hove, President and CEO of Revelle Aesthetics. ‘Equally as exciting is the role that we believe Avéli will play as a cornerstone in the latest and fastest growing category in medical aesthetics, lower body rejuvenation.’
Cellulite is a depression of any shape or size with a defined edge, typically on the buttocks or thighs, and affects up to 90% of women. A major underlying cause of cellulite is the complex structure of fibrous septa bands that tether the skin. Some septa stiffen or shrink over time and lead to the dimples we see on the skin’s surface.
Unlike many current cellulite options, Avéli addresses cellulite from the inside-out. It is the only minimally invasive procedure that allows a provider to identify which of the fibrous septa bands are causing a cellulite dimple, and then confirm in real-time they are releasing those targeted septa to deliver visibly smoother skin. Results are visible quickly after a single in-office procedure with little-to-no downtime.
Avéli is now available across the US, growing rapidly in plastic surgery and dermatology practices that are focused on the rising needs in body contouring.
